Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy
Angela Sánchez1,2, Belén García-Lareu1, Meritxell Puig1,2
1Department of Biochemistry and Molecular Biology and Institute of Neurosciences, Edifici H, Universitat Autònoma de Barcelona, E-08193, Bellaterra, Spain.
Summary
Gene therapy successfully treated a rare genetic disorder, megalencephalic leukoencephalopathy with subcortical cysts (MLC), in mice. This preclinical study offers hope for a potential treatment for MLC patients and other motor function disorders.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare genetic disorder characterized by megalencephaly, motor dysfunction, and epilepsy.
- Current treatments for MLC are limited to supportive care, with no specific therapies available.
- Vacuoles in myelin and astrocytes are key pathological hallmarks of MLC.
Purpose of the Study:
- To evaluate a preclinical gene therapy approach for Megalencephalic leukoencephalopathy with subcortical cysts (MLC).
- To investigate both preventive and therapeutic potential of gene therapy for MLC.
- To assess the efficacy of adeno-associated virus-mediated gene delivery of MLC1.
Main Methods:
- Adeno-associated virus carrying human MLC1 was administered via cerebellar subarachnoid injection in Mlc1 knock-out and wild-type mice.
- Injections were performed at different ages (2, 5, and 15 months) to test preventive and therapeutic strategies.
- Restoration of GlialCAM and ClC-2 localization in Bergmann glia was assessed.
Main Results:
- MLC1 gene therapy restored the localization of GlialCAM and ClC-2 in Bergmann glia of treated mice.
- Myelin vacuolation was significantly reduced in treated Mlc1 knock-out mice across all tested ages.
- The reduction in vacuolation correlated with the level of expressed MLC1, demonstrating dose-dependent efficacy.
Conclusions:
- This study presents the first preclinical gene therapy approach for Megalencephalic leukoencephalopathy with subcortical cysts (MLC).
- The gene therapy demonstrated both preventive and therapeutic potential, significantly reducing key pathological features.
- This approach may offer a future treatment for MLC and potentially other motor function disorders like ataxias.
